Brittany Lovely

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

Further investigation into the outcomes of adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia when treated with pediatric-inspired regimens are warranted.

After positive results from the phase 1/2 KRT-232-109 study, the phase 3 BOREAS-2 study will further evaluate the combination of navtemadlin and ruxolitinib in patients with myelofibrosis.

Results from the DESTINY-CRC02 study showed that a lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

CLDN6-directed CAR T-cell therapy used with or without a CLDN6-encoding mRNA vaccine continues to show promise in advanced solid tumors.

Results from an age group analysis of the monarch E trial reveal continued efficacy and safety with the experimental regimen, abemaciclib plus endocrine therapy.

Though not statistically significant, data from the PROpel study of abiraterone acetate and olaparib were noted to be the longest overall survival results seen in a first-line phase 3 trial in metastatic castration-resistant prostate cancer.

Modest clinical benefit elicited with or without bevacizumab added to atezolizumab (Tecentriq) plus cisplatin/gemcitabine in biliary tract cancer.

In the real-world setting. Patients treated with the chimeric antigen receptor T-cell agent, axicabtagene ciloleucel experience similar quality-of-life outcomes to patients who were treated in clinical trials.

Results from the GeparOLA study show that neoadjuvant olaparib did not achieved better efficacy compared with carboplatin and paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

The data from 2 years post primary efficacy analysis of monarchE study showed that adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival.

The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.

A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.

New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

Results of a phase 1 trial of the bispecific antibody ABBV-383 showed a high overall response rate and manageable adverse event profile in patients with relapsed/refractory multiple myeloma.

Results shown from studies of bispecific antibodies, immunomodulatory drugs , and antibody-drug conjugates signal a bright future for relapsed or refractory myeloma treatment.

Recent data reported from the MOUNTAINEER will support a new drug application for tucatinib in patients with metastatic colorectal cancer.

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.

Following treatment osimertinib, EGFR C797X mutations are now the leading mechanism of acquired resistance, outpacing MET amplification.

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor in patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

At the 2022 American Society for Clinical Oncology Annual Meeting, durable responses continued to be shown with asciminib compared with bosutinib in adult patients with chronic myeloid leukemia in chronic phase.

Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.

A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.

Metastatic triple-negative breast cancer appears to derive clinical benefit from sacituzumab govitecan-hziy overtime, regardless of patients’ HER2 expression, according to a post hoc analysis of the phase 3 ASCENT trial.

An analysis of the ZUMA-5 and ELARA shows that the 2 CAR T-cell therapies, axicabtagene ciloleucel, and tisagenlecleucel have similar efficacy.

Match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in the ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar outcomes in regard to efficacy between the 2 cellular therapies.

Full-dose pacritinib beats ruxolitinib in patients with cytopenic myelofibrosis.

Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.

Phase 2 study results signal benefit of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutant non–small cell lung cancer.